Pharmaceuticals
December 21, 2023
Katarina Savić Vujović, Ana Jotić, Branislava Medić et al.
32 citations
Ketamine as an old-new drug has a variety of clinical implications. In the last 30 years, ketamine has become popular for acute use in humans. Ketamine in standard doses is principally utilized for the induction and maintenance of surgical procedures. Besides its use in anesthesia and analgesia, recent studies have shown that ketamine has found a place in the treatment of asthma, epilepsy,...
Theoretical and Natural Science
December 20, 2023
Jingxuan Chen
Psilocybin is a naturally occurring psychoactive compound, which has been used for ages in traditional settings for religious and therapeutic use. Recent studies have renewed interest in psilocybin for its potential therapeutic benefits in treating depression and anxiety. The pharmacodynamics of psilocybin are complex, involving its rapid conversion to psilocin and its activity on various...
Translational Psychiatry
December 14, 2023
Ivan Skorodumov, Rainer Spanagel, Jonathan R Reinwald et al.
25 citations
Abstract Alcohol Use Disorder (AUD) adversely affects the lives of millions of people, but still lacks effective treatment options. Recent advancements in psychedelic research suggest psilocybin to be potentially efficacious for AUD. However, major knowledge gaps remain regarding (1) psilocybin’s general mode of action and (2) AUD-specific alterations of responsivity to psilocybin treatment in...
Drug and Alcohol Dependence
December 1, 2023
Caryssa R Drinkuth, Michael J Lehane, Gregory C Sartor
9 citations
Despite the thousands of lives lost during the ongoing opioid crisis, a scarcity of new and effective clinical treatments for opioid use disorder (OUD) remains. To address this unmet need, some researchers have turned to dissociative and psychedelic drugs to treat multiple psychiatric conditions. In particular, low doses of ketamine have been shown to attenuate opioid withdrawal and drug use in...
Journal of Psychopharmacology
December 1, 2023
Brian J Gully, Erica Eaton, Christy Capone et al.
12 citations
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur in patients who have experienced trauma. This comorbidity leads to a vicious cycle where PTSD symptoms beget heavy drinking and vice versa. There are no FDA-approved medications to treat PTSD-AUD; therefore, individuals suffering from this comorbidity are treated with medication approved to treat the...
Journal of Psychopharmacology
December 1, 2023
Genís Ona, Ingrid Reverte, Giordano N. Rossi et al.
20 citations
There is a growing interest in studying ibogaine (IBO) as a potential treatment for substance use disorders (SUDs). However, its clinical use has been hindered for mainly two reasons: First, the lack of randomized, controlled studies informing about its safety and efficacy. And second, IBO's mechanisms of action remain obscure. It has been challenging to elucidate a predominant mechanism of...
Psychedelic Medicine
December 1, 2023
Julia Malicki, Amelia Baltes, Christopher R. Nicholas et al.
7 citations
Coadministration of psilocybin and buprenorphine was safely tolerated and did not demonstrate contraindicating effects vis-à-vis effectiveness of buprenorphine or the subjective effects of psilocybin. Challenges in feasibility led to modifications in the sample population and eligibility criteria and strategies to improve accessibility, minimize burden, and enhance overall...
Toxics
November 28, 2023
Emeline Gernez, Graham Robert Lee, Jean-Paul Niguet et al.
The recreational use of nitrous oxide (N2O), also called laughing gas, has increased significantly in recent years. In 2022, the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) recognized it as one of the most prevalent psychoactive substances used in Europe. Chronic nitrous oxide (N2O) exposure can lead to various clinical manifestations. The most frequent symptoms are...
Psychoactives
November 17, 2023
Anna Beatriz Vicentini, Lucas Silva Rodrigues, Giordano Novak Rossi et al.
4 citations
Alcohol is the recreational drug most frequently consumed, and its high frequency of use can lead to worsening social, psychological, and domestic issues. The age group most susceptible to alcohol dependence is 18- to 24-year-old youths, demanding interventional tools to target early involvement risks. Ayahuasca seems to be a promising therapeutic tool since evidence suggests it presents...
Frontiers in Psychiatry
November 13, 2023
Tor-Morten Kvam, Malin V. Uthaug, Kristoffer A A Andersen et al.
21 citations
Objective In recent years, there has been a renewed interest in investigating the use of classic psychedelics such as psilocybin and lysergic acid diethylamide (LSD) in the treatment of mental disorders and substance use disorders. However, knowledge about the epidemiology of classic psychedelics in the Nordic countries is limited. Methods We recruited adult, Norwegian participants who have had...
Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
November 7, 2023
Naoto Matsuda, Hiroaki Wakakuri, Kazuyuki Uehara et al.
Nitrous oxide (N2O) is readily available, and its abuse for recreational purposes has become a social problem. In Japan, where N2O is strictly prohibited for non-medical use, abuse is often overlooked due to a lack of experience in the field. N2O abuse causes various long-term symptoms, including vitamin B12 deficiency, myelopathy, myeloneuropathy, subacute combined degeneration, mood changes,...
The American Journal of Drug and Alcohol Abuse
November 2, 2023
Fernando Mendive, Cecile Giovannetti, Sara García Arce
4 citations
Background: There exists an underexploited opportunity to develop innovative therapeutic approaches to SUDs based upon the complementarity between modern and traditional health systems.Objectives: Illustrate the feasibility and potentiality of such an approach through the comprehensive description of Takiwasi Center's treatment model and program, where health concepts and practices from...
Psychological Medicine
November 2023
Matthew N Hill, Margaret Haney, Cecilia J. Hillard et al.
Cannabis is well established to impact affective states, emotion and perceptual processing, primarily through its interactions with the endocannabinoid system. While cannabis use is quite prevalent in many individuals afflicted with psychiatric illnesses, there is considerable controversy as to whether cannabis may worsen these conditions or provide some form of therapeutic benefit. The...
Journal of Health, Medicine and Nursing
November 1, 2023
Prince Opuni Frimpong
1 citation
Ketamine, a dissociative anesthetic commonly used in medical settings, has shown promising results in treating various mental health disorders. Recent studies have suggested its potential repurposing for treating cocaine use disorder (CUD). However, before implementing such a treatment approach, it is crucial to consider the ethical and legal constraints associated with it from a Ghanaian...
American Journal on Addictions
November 1, 2023
Amanda Kim, Joji Suzuki
15 citations
In recent years, there has been accelerating scientific and public interest in the use of psychedelics to treat mental health disorders. Our study's objective was to assess the attitudes of addiction specialists regarding therapeutic psychedelics. Our study utilized an anonymous online survey to assess the opinions of 145 addiction specialists regarding the therapeutic promise, potential risks,...
Advancement in Yoga and Physical Therapy
October 31, 2023
2 citations
On invitation to write an article on Yoga here we decided to write on science of Raj yoga meditation (RM). Normally besides the classic asana-based meditations there are 3 kinds of meditations i) Contemplation/ Concentration based ii) Mindful based iii) Love kind of meditation. Despite so much scepticism the western world found results with meditation and according to them Mindful based...
October 30, 2023
Jeremy Weleff, Julio C Nunes, Gabriel P. A. Costa et al.
The rise of psychedelics in contemporary medicine has sparked interest in their potential therapeutic applications. While traditionally associated with countercultural movements and recreational use, recent research has shed light on the potential benefits of psychedelics in various mental health conditions. In this review, we explore the emerging role of psychedelics in the management of...
Annals of Pharmacotherapy
October 30, 2023
Dana Kaminski, Justin P. Reinert
21 citations
Objective: The objective of this systematic review is to determine the tolerability and safety of psilocybin in a variety of psychiatric and substance-dependence conditions. Data sources: A systematic review was conducted using Embase, PubMed, Cochrane Central, and Web of Science through September 2023 using the following terminology: “psilocybin” AND “mental-disease” OR “substance-dependence”...
Frontiers in Psychiatry
October 19, 2023
Brian S. Barnett, Anahita Bassir Nia, Nathan Sackett et al.
1 citation
Disclosures of Financial or Other Potential Conflicts of Interest: Dr. Barnett holds stock options in CB Therapeutics. He also serves on advisory boards for CB Therapeutics and Compass Pathways. He receives monetary compensation from DynaMed Plus (EBSCO Industries, Inc.) for editorial work and from Janssen Pharmaceuticals for consulting services. Dr. Barnett has received research funding from...
BMC Neuroscience
October 18, 2023
Anastasia Demina, Benjamin Petit, Vincent Meille et al.
20 citations
BACKGROUND: High-quality evidence is still required to affirm the efficacy of mindfulness-based interventions (MBIs) in craving reduction. MBIs may be particularly appropriate for this purpose given the neurobiological mechanisms of addiction with automatic behavior in response to the negative affect. In this systematic review and meta-analysis, we aimed to study the efficacy of MBIs in craving...